The CheckRare Brief Podcast +++ New FDA Approvals for Rare Diseases: From Autoimmune Disorders to Pancreatic Cancer | The CheckRare Brief Ep 5 by CheckRare Staff| Published on: Sep 3, 2026

The CheckRare Brief Podcast New FDA Approvals for Rare Diseases: From Autoimmune Disorders to Pancreatic Cancer | Ep 5 New FDA Approvals for Rare Diseases: From Autoimmune Disorders to Pancreatic Cancer | The CheckRare Brief Ep 5 by CheckRare Staff| Published on: Sep 3, 2026 In this episode of The CheckRare Brief, we discuss four recent FDA approvals, including LISRAYA for dermatomyositis and Imaavy for warm autoimmune hemolytic anemia (wAIHA), Mimrylo for polycythemia vera (PV), and Rasonque for pancreatic cancer. https://checkrare.com/new-fda-approvals-for-rare-diseases-from-autoimmune-disorders-to-pancreatic-cancer-the-checkrare-brief-ep-5/ Getting a Rare Disease Drug Approved Is Only Half the Battle | Ep 4 Two new rare disease approvals, ongoing drug supply problems affecting patients, and a major acquisition that illustrates how rare disease therapies move from small biotech companies into the hands of larger pharmaceutical companies. https://checkrare.com/getting-a-rare-disease-drug-approved-is-only-half-the-battle-the-checkrare-brief-ep-4/ FDA Approves Multiple Myeloma Treatment, Denies Neuroendocrine Tumors Treatment | Ep 3 FDA’s approval of Zenbexus (iberdomide) to treat patients with multiple myeloma, the complete response letter issued to ITM-11 to treat patients with neuroendocrine tumors, and safety concerns about VYKAT XR for Prader-Willi syndrome (PWS). https://checkrare.com/fda-approves-multiple-myeloma-treatment-denies-neuroendocrine-tumors-treatment/